University of Pennsylvania Bioengineers Redesign mRNA Vaccine Delivery to Eliminate Common Side Effects While Triple-Targeting Lymph Nodes

New 2026 study shows modified lipid nanoparticles boost mRNA vaccine delivery to lymph nodes by 3x while reducing fever and fatigue in patients.

By: AXL Media

Published: Mar 18, 2026, 8:50 AM EDT

Source: Information for this report was sourced from University of Pennsylvania School of Engineering and Applied Science

Breaking the Efficacy and Side Effect Trade Off

A transformative study from the University of Pennsylvania School of Engineering and Applied Science has challenged the long-held medical assumption that vaccine efficacy must come at the cost of physical discomfort. Traditionally, the soreness, fever, and malaise associated with mRNA vaccines are viewed as necessary evidence of a robust immune response. However, by re-engineering the lipid nanoparticles (LNPs) that carry the genetic instructions, researchers have demonstrated that it is possible to maintain high levels of protection while suppressing the inflammatory signals that cause systemic illness. Senior author Michael J. Mitchell noted that this chemical intervention opens the door to a new generation of "better tolerated" vaccines that prioritize both potency and patient comfort.

From Delivery Vehicle to Metabolic Regulator

The breakthrough centers on a fundamental reimagining of what a lipid nanoparticle can achieve. Historically treated as simple "delivery trucks" for mRNA cargo, the Penn team has shown that LNPs can actively modify the internal metabolism of the cells they enter. By adding a new chemical ingredient known as an imidoester cross-linker, researchers created a specific lipid dubbed C12-2aN. This compound effectively "shifts the gears" of dendritic cells—the primary instructors of the immune system—by boosting their ability to produce energy through glycolysis. This metabolic surge provides the cells with the fuel necessary to mount a defense without triggering the widespread inflammatory cascade typically seen after vaccination.

Reducing Systemic Inflammation and Fever

One of the most significant outcomes of the C12-2aN modification is its ability to confine immune activation to the target cells. In pre-clinical tests involving human cells and mouse models, the redesigned lipid significantly lowered the expression of genes associated with systemic inflammation. Unlike standard FDA-approved formulations that often cause a spike in body temperature, mice treated with the modified LNPs experienced minimal increases in heat. Amanda Murray, a co-author of the study, explained that the dendritic cells receive the energy they need for a protective response while the body avoids the "cytokine storm" markers in the bloodstream that lead to muscle aches and general fatigue.